IfPA papers examine policy issues and regulatory decisions that impact patient access – in language that everybody can understand.

Policy Briefs

Biosimilars: Expanding Options for Cancer Care
A Path to Hepatitis C Elimination for Policymakers

2021

2020

2018

2017

2016

2015

2014

2013

Biosimilars: Expanding Options for Cancer Care
A Path to Hepatitis C Elimination for Policymakers
Precision Medicine: Redefining Care for Rheumatoid Arthritis
In Conversation: A Physician Discusses COVID-19 & Rare Disease
In Conversation: A Physician Discusses COVID-19 & Dermatological Care
In Conversation: A Physician Discusses COVID-19 & Osteoarthritis Care
In Conversation: A Physician Discusses COVID-19 & Diabetes Care
In Conversation: A Physician Discusses COVID-19 & Migraine Treatment
In Conversation: A Physician Discusses COVID-19 & Cardiovascular Care
In Conversation: A Physician Discusses COVID-19 & Home Infusion
In Conversation: A Nurse Practitioner Discusses COVID-19 & Infant Health
Botulinum Neurotoxins and Non-Medical Switching
Worth It?
Myths, Facts & Respiratory Syncytial Virus
Co-Pay Accumulator Programs: What Can Policymakers Do to Protect Patients?
Co-pay Accumulator Adjustment Programs
Physician’s Perspective: Asthma & Non-Medical Switching
How Physicians View the 340B Drug Pricing Program
Testing and Treating Prisoners for Hepatitis C
Oncology Value Models
Improving Cancer Patients’ Access to Precision Medicine
Clinical Practice Guidelines and Patient Access
Access to Hepatitis C Cures for Medicaid Patients
Multimodal Analgesia: Acute Pain Relief for the Whole Patient
Medication for Long-Term Care Residents: Reducing Overuse Without Compromising Access and Care
Improving Patient Access to Immuno-Oncology Therapies
Unresolved Policy Issues Impact Patient Access to Biosimilars
Informed Prescribing: Physicians Need Complete and Specific Prescribing Information for Biosimilar Medications
Access to Integrated Care for Chronic Pain
Abuse-Deterrent Opioid Formulations: Promising Technology, Unique Challenges
What is Indication Extrapolation and Should it be Allowed with Biological Medications?
Ensure Patient Safety When Naming Biological Medications
The True Costs of Health Plan Specialty Tiers